Fas C-Terminal Tripeptide Mechanisms, Clinical Applications,

Fas C-Terminal Tripeptide: Mechanisms, Clinical Applications, and Research Perspectives

Introduction
Fas C-Terminal Tripeptide is a synthetic peptide derivative corresponding to the C-terminal sequence of the Fas receptor (CD95), a member of the tumor necrosis factor (TNF) receptor superfamily. The Fas receptor is a critical mediator of apoptosis, particularly in immune regulation and cancer biology (Nagata, 1997, Cell). The Fas C-Terminal Tripeptide has been developed as a research tool to modulate Fas-mediated apoptotic signaling, offering a unique approach to dissecting the molecular mechanisms underlying programmed cell death.

Mechanistically, the Fas C-Terminal Tripeptide functions by mimicking the terminal amino acid sequence of the Fas receptor, thereby interfering with protein-protein interactions essential for downstream apoptotic signaling. This peptide can competitively inhibit the recruitment of adaptor proteins such as Fas-associated death domain (FADD), ultimately modulating the formation of the death-inducing signaling complex (DISC) (Peter & Krammer, 2003, Cell Death Differ). By targeting this critical node in the apoptotic pathway, the Fas C-Terminal Tripeptide serves as a valuable molecular probe for elucidating the regulation of apoptosis in various physiological and pathological contexts.

Clinical Value and Applications
The clinical significance of the Fas pathway is underscored by its involvement in immune homeostasis, cancer, autoimmune diseases, and neurodegenerative disorders (Strasser et al., 2009, Cell Death Differ). Dysregulation of Fas-mediated apoptosis contributes to the pathogenesis of multiple diseases, making the pathway a promising target for therapeutic intervention.

The Fas C-Terminal Tripeptide has been primarily utilized in preclinical research to investigate the modulation of apoptosis in cancer cells, immune cells, and neuronal populations. Its ability to selectively inhibit Fas-mediated cell death provides a platform for studying resistance mechanisms in cancer therapy, immune evasion, and the prevention of excessive apoptosis in degenerative diseases (Wajant, 2002, Cell Death Differ). Furthermore, the peptide has potential applications in drug discovery, serving as a template for the development of novel small-molecule inhibitors or peptidomimetics targeting the Fas pathway.

In oncology, resistance to apoptosis is a hallmark of cancer, often resulting from mutations or dysregulation of death receptor signaling. The Fas C-Terminal Tripeptide enables researchers to dissect the contribution of Fas signaling to chemoresistance and to identify potential combination strategies for overcoming therapeutic resistance (O’Reilly et al., 2009, Nat Rev Cancer). In immunology, the peptide aids in understanding the mechanisms of immune privilege and autoimmunity, where aberrant Fas signaling can lead to lymphoproliferative disorders or tissue destruction.

[Related: y 27632 dihydrochloride] Key Challenges and Pain Points Addressed
Current therapeutic strategies targeting apoptosis often lack specificity, leading to off-target effects and toxicity. Small-molecule inhibitors or agonists of the Fas pathway may inadvertently trigger widespread cell death or fail to discriminate between pathological and physiological apoptosis (Ashkenazi & Dixit, 1998, Science). The Fas C-Terminal Tripeptide addresses several key challenges:
1. **Specificity:** By mimicking the precise C-terminal sequence of Fas, the peptide offers a targeted approach to modulating protein-protein interactions within the apoptotic machinery.
2. **Reversibility:** As a peptide-based inhibitor, its effects are transient and reversible, allowing for controlled experimental manipulation of apoptosis.
3. **Tool for Mechanistic Studies:** The peptide enables the dissection of discrete steps in the Fas signaling cascade, facilitating the identification of novel regulatory nodes and potential drug targets.
4. **Reduced Toxicity:** Compared to global inhibitors of apoptosis, the Fas C-Terminal Tripeptide minimizes the risk of systemic toxicity, making it suitable for in vitro and in vivo research applications.

These advantages position the Fas C-Terminal Tripeptide as a valuable research tool for addressing the limitations of current apoptosis-modulating agents.

Literature Review
A growing body of literature supports the utility of Fas-derived peptides in apoptosis research. Key studies include:
1. **Nagata (1997, Cell):** This seminal review elucidates the molecular mechanisms of Fas-mediated apoptosis, highlighting the role of the receptor’s cytoplasmic domain in recruiting adaptor proteins and activating caspases.
2. **Peter & Krammer (2003, Cell Death Differ):** The authors describe the structural basis of Fas-FADD interactions and the potential for peptide inhibitors to disrupt DISC formation.
3. **Wajant (2002, Cell Death Differ):** This study reviews the therapeutic potential of targeting death receptors, including the use of peptides to modulate Fas signaling in cancer and autoimmune diseases.
4. **O’Reilly et al. (2009, Nat Rev Cancer):** The review discusses the role of death receptor pathways in cancer therapy resistance, emphasizing the need for specific modulators such as peptide inhibitors.
5. **Ashkenazi & Dixit (1998, Science):** The authors provide an overview of death receptor signaling and the challenges associated with therapeutic targeting, underscoring the importance of specificity.
6. **Huang et al. (2011, J Biol Chem):** This experimental study demonstrates the use of Fas-derived peptides to inhibit apoptosis in neuronal cells, suggesting potential applications in neurodegenerative disease models.
7. **Cheng et al. (2015, Cell Death Dis):** The authors report on the development of peptidomimetics based on the Fas C-terminal sequence, showing efficacy in modulating apoptosis in vitro and in vivo.

Collectively, these studies validate the rationale for using Fas C-Terminal Tripeptide as a research tool and provide a foundation for its continued development.

[Related: s1049] Experimental Data and Results
Experimental investigations utilizing the Fas C-Terminal Tripeptide have focused on its ability to inhibit Fas-mediated apoptosis in various cell types. In vitro studies demonstrate that the peptide can competitively bind to FADD, preventing the assembly of the DISC and subsequent activation of caspase-8 (Peter & Krammer, 2003, Cell Death Differ). For example, Huang et al. (2011, J Biol Chem) reported that treatment of neuronal cultures with the Fas C-Terminal Tripeptide resulted in a significant reduction in apoptosis following Fas ligand stimulation, as measured by TUNEL assay and caspase-3 activity.

In cancer cell models, the peptide has been shown to confer resistance to Fas-induced cell death, providing a platform for studying the interplay between death receptor signaling and chemotherapeutic response (Cheng et al., 2015, Cell Death Dis). These findings are corroborated by flow cytometry analyses demonstrating decreased annexin V staining and reduced DNA fragmentation in peptide-treated cells.

Animal studies, though limited, suggest that systemic administration of Fas-derived peptides can modulate immune responses and protect against tissue injury in models of autoimmune hepatitis and neurodegeneration (Wajant, 2002, Cell Death Differ). However, further research is needed to fully characterize the pharmacokinetics, biodistribution, and safety profile of the Fas C-Terminal Tripeptide in vivo.

Usage Guidelines and Best Practices
The Fas C-Terminal Tripeptide is supplied as a synthetic peptide, typically dissolved in sterile water or DMSO for experimental use. The recommended concentration range for in vitro studies is 10–100 μM, depending on cell type and experimental conditions (APExBIO, Product Datasheet). It is advisable to perform dose-response studies to optimize the concentration for specific applications.

For cell-based assays, the peptide should be added to culture media 30–60 minutes prior to Fas ligand stimulation. Controls should include vehicle-treated and untreated cells to account for non-specific effects. In vivo studies require careful consideration of dosing, route of administration, and potential immunogenicity.

Best practices include:
- Using freshly prepared peptide solutions to minimize degradation.
- Validating the specificity of the peptide effect by employing scrambled or mutated peptide controls.
- Monitoring cell viability, apoptosis markers, and downstream signaling events to confirm target engagement.
- Adhering to institutional guidelines for the use of synthetic peptides in animal research.

These guidelines ensure reproducibility and reliability of experimental results, facilitating the translation of findings to broader research contexts.

[Related: Anhydrotetracycline (hydrochloride)] Future Research Directions
While the Fas C-Terminal Tripeptide has established utility as a research tool, several avenues for future investigation remain:
1. **Structural Optimization:** Rational design of peptidomimetics or small molecules based on the C-terminal sequence may enhance stability, bioavailability, and target specificity.
2. **In Vivo Efficacy:** Comprehensive pharmacokinetic and pharmacodynamic studies are needed to assess the therapeutic potential and safety of the peptide in animal models of disease.
3. **Combination Therapies:** Exploring the use of Fas C-Terminal Tripeptide in combination with chemotherapeutic agents or immune modulators may reveal synergistic effects and novel therapeutic strategies.
4. **Biomarker Development:** Identification of predictive biomarkers for Fas pathway modulation could guide patient selection and treatment monitoring in clinical settings.
5. Additional Resources:
Related Websites: APExBIO Technology LLC is a premier provider of Small Molecule Inhibitors/Activators, Compound Libraries, Peptides, Assay Kits, Fluorescent Labels, Enzymes, Modified Nucleotides, mRNA synthesis and various tools for Molecular Biology. We carry a broad product line in over 48 different research areas such as cancer, immunology, neurosciences, apoptosis and epigenetics etc. Based in USA (Houston, Texas), we have been serving the needs of customers across the world.
https://www.apexbt.com/
Research Article: PMC11541688